D59.0 Drug-induced autoimmune hemolytic anemia

Name of the Condition

• Drug-induced autoimmune hemolytic anemia (ICD-10 Code: D59.0)

Summary

Drug-induced autoimmune hemolytic anemia is a condition where the immune system mistakenly attacks red blood cells, leading to their premature destruction. This occurs as a reaction to certain medications, resulting in anemia. The condition is characterized by the body producing antibodies that target red blood cells, reducing their lifespan and impairing oxygen transport.

Causes

The primary cause is an adverse immune response triggered by specific drugs. These medications can induce the production of antibodies that bind to red blood cells, marking them for destruction. Common culprits include certain antibiotics, antimalarials, and anti-inflammatory drugs, though the exact mechanism varies by drug.

Risk Factors

• Use of medications known to trigger immune reactions (e.g., penicillins, cephalosporins, or methyldopa)
• Prior history of drug-induced hemolytic anemia
• Underlying autoimmune conditions that may predispose to immune dysregulation

Symptoms

• Fatigue and weakness
• Pale or yellowish skin (jaundice)
• Dark urine
• Shortness of breath
• Rapid heart rate
• Enlarged spleen (splenomegaly)
• Dizziness or lightheadedness

Diagnosis

Diagnosis involves blood tests to assess red blood cell destruction and anemia, including a complete blood count (CBC), direct antiglobulin test (DAT), and reticulocyte count. Additional tests may evaluate bilirubin levels, lactate dehydrogenase (LDH), and haptoglobin to confirm hemolysis. A detailed medication history is critical to identify the triggering drug.

Treatment Options

• Discontinuation of the offending drug, if identified
• Corticosteroids to suppress the immune response
• Blood transfusions in severe cases with significant anemia
• Intravenous immunoglobulin (IVIG) for refractory cases
• Supportive care, including monitoring for complications

Prognosis and Follow-Up

Prognosis is generally favorable with prompt discontinuation of the causative drug and appropriate treatment. Most patients recover fully, though recovery time varies. Follow-up includes monitoring blood counts and symptoms to ensure resolution and to detect any recurrence.

Complications

• Severe anemia requiring urgent intervention
• Acute kidney injury due to hemoglobin release
• Transfusion reactions if blood transfusions are needed
• Chronic fatigue or weakness if recovery is prolonged

Lifestyle & Prevention

• Avoid known triggering medications, if possible
• Inform healthcare providers of any history of drug-induced reactions
• Maintain regular follow-up with a hematologist or primary care physician
• Monitor for symptoms and report changes promptly

When to Seek Professional Help

Seek immediate medical attention if experiencing severe fatigue, jaundice, dark urine, or shortness of breath, as these may indicate worsening anemia or complications. Prompt evaluation is essential to identify and discontinue the causative drug and initiate treatment.

Tips for Medical Coders

When coding D59.0, ensure the documentation clearly links the anemia to a drug-induced autoimmune process. Verify that the medical record specifies the triggering medication and confirms the autoimmune mechanism (e.g., via DAT results). Document any associated treatments or complications to support code assignment. Avoid coding if the anemia is due to non-drug causes or if the autoimmune nature is not established.